She received infusions of intravenous immunoglobulin twice a month for 6 months. At her last follow-up visit, she was seizure-free and neurologically intact except for mild inattention.
■ NEWLY RECOGNIZED DISEASES
Although autoantibody-mediated encephalitic syndromes were first described more than 50 years ago, 1,2 their autoimmune basis was not recognized until the early 1980s. 3 In the past 10 years, a flood of novel clinical syndromes associated with neuronal autoantibodies has been described that may be markedly improved or even completely resolved with immunotherapy. In cases of unexplained seizure, encephalitis, or acute-onset psychiatric syndromes, suspecting these syndromes can lead to diagnosis, treatment, and a good outcome.
This review describes the key clinical autoantibody-mediated encephalitic syndromes, explains the better-characterized antibody associations, and discusses their diagnosis and treatment.
■ CLASSIFIED ANATOMICALLY, IMMUNOLOGICALLY, OR EPONYMOUSLY
Autoantibody-mediated encephalitis is also known as autoimmune-mediated encephalitis, autoimmune-mediated limbic encephalitis, and autoimmune synaptic encephalitis. How to categorize these syndromes is still in flux: they can be listed by the area of the brain affected, the antibody involved, or the name of the discoverer (eg, Morvan syndrome).
Autoantibodies identified in autoimmune encephalitis fall under two broad categories:
• Those targeting intracellular (intranuclear or intracytoplasmic) antigens; the syndromes they cause are more likely to be paraneoplastic and less responsive to immunotherapy • Those targeting antigens on the neuronal surface: the syndromes they cause are less likely to be paraneoplastic and are more responsive to immunotherapy. 4 ■ SYNDROMES DEFINED BY BRAIN AREA AFFECTED Below, we provide examples of neurologic syndromes of autoantibody-mediated encephalitis according to the region of the brain most affected, ie, the limbic system, the brainstem, or the cerebellum (Figure 2 ).
■ LIMBIC ENCEPHALITIS Memory loss, behavioral changes, seizures
Patients with limbic encephalitis (such as the patient described in the vignette above) present with symptoms attributed to dysfunction of mesial temporal lobe structures, most notably the hippocampus. Prominent symptoms include short-term memory loss, behavioral disturbances such as agitation and confusion, and psychiatric problems such as depression and psychosis. Recurrent seizures are a salient feature and, not uncommonly, progress to status epilepticus. 
Antibodies are not all cancer-associated
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VGKC-voltage-gated potassium channel JAMMOUL AND COLLEAGUES vation, eg, slight pleocytosis, elevated protein, increased immunoglobulin G synthesis, and oligoclonal banding. 5 In many cases, an autoantibody is found in the blood or in the cerebrospinal fluid. Some patients may express more than one autoantibody, so the traditional view of "one antibody, one syndrome" is incorrect.
Although initially identified as a rare paraneoplastic disorder, limbic encephalitis sometimes occurs in the absence of malignancy.
Multiple antibodies have been linked to the syndrome (Table 1) . [6] [7] [8] [9] The "classic" antibodies initially found in paraneoplastic forms are now generally viewed as nonpathogenic, in part because they are directed against intracellular antigens. Neuronal injury in paraneoplastic limbic encephalitis is believed to be mediated by cytotoxic T lymphocytes, with neuronal autoantibodies being produced after the injury. 4 Recently defined antibodies, such as those targeting the N-methyl-d-aspartate (NMDA) receptor 6 and the LGI1 protein, 7 are now understood to be common causes of limbic encephalitis.
Imaging usually shows limbic focal changes
Structural MRI or functional fluorodeoxyglucose (FDG)-PET imaging may show focal changes in limbic system structures, such as the mesial temporal lobes. It is now recognized that other cortical areas may be involved, and the term "limbic encephalitis" may give way to "cortical" or "focal encephalitis." In about 60% of patients, MRI shows hyperintense fluid-attenuated inversion recovery (FLAIR) or T2 signal changes in the mesial temporal lobes, likely reflecting inflammatory changes. 4, 10, 11 On FDG-PET, hypermetabolism may be observed in the mesial temporal lobes early in the disease despite normal findings on MRI. 12 Hypometabolism, either diffuse or localized to the mesial temporal lobes, eventually sets in, likely reflecting cytotoxic injury in the aftermath of prolonged inflammation or seizures.
Consider other causes
Before diagnosing limbic encephalitis, it is essential to evaluate for infectious meningoencephalitis, especially herpes simplex viral encephalitis. Thiamine deficiency (WerHow to categorize these syndromes is still in flux Autoantibody-mediated encephalitis can be classified either by the antibody responsible or by the area of the brain affected, and therefore the presenting symptoms. The structures affected include:
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The limbic system. Symptoms: 
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■ BRAINSTEM ENCEPHALITIS
The brainstem-the midbrain, pons, and medulla-can be affected, either in isolation or more commonly as part of a more widespread autoantibody-mediated encephalitis. Symptoms and signs include eye movement abnormalities, ptosis, dysphagia, dysarthria, ataxia, facial palsy, vertigo, hearing impairment, reduced consciousness, and hypoventilation. 21 Anti-Hu, anti-Ri, and anti-Ma2 antibodies are most commonly associated with brainstem encephalitis ( Table 2) . Anti-Ma2-associated encephalitis may improve after a combination of immunotherapy and tumor removal 21 ; the others have a poor prognosis.
Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders most commonly involve demyelination affecting the optic nerves and spinal cord, leading to unilateral or bilateral optic neuritis and transverse myelitis spanning three or more vertebral segments. 22 The initial clinical manifestation may be an encephalitic pattern, affecting predominantly the brainstem in a restricted fashion, 22 or the central nervous system in a more diffuse pattern, mimicking either acute disseminated encephalomyelitis or, in less severe cases, posterior reversible encephalopathy syndrome. Anti-AMPA receptor 70% Thymoma, breast, lung Good Anti-GABA B receptor 47% Small cell lung cancer Good AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANNA1 = antineuronal nuclear antibody 1; CRMP = collapsin-responsive mediated protein; GABA B = gamma-aminobutyric acid; GAD = glutamic acid decarboxylase; LGI1 = leucine-rich glioma-inactivated protein 1; NMDA = N-methyl-daspartate; VGKC = voltage-gated potassium channel
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Testing for antiaquaporin-4 antibody, also known as neuromyelitis optica immunoglobulin G, is the single most decisive laboratory test for diagnosing neuromyelitis optica spectrum disorders, so serum and cerebrospinal fluid evaluation for this autoantibody should be considered when caring for a patient whose clinical picture suggests brainstem encephalitis.
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Bickerstaff brainstem encephalitis Bickerstaff brainstem encephalitis was first described more than half a century ago in patients with postinfectious ataxia, ophthalmoparesis, and altered consciousness. This rare disease was later found to be associated with antiganglioside GQ1b (anti-GQ1b) autoantibody. MRI is normal in about 90% of cases, so recognizing the clinical presentation and analyzing anti-GQ1b serum titers are critical to diagnosis.
Recovery is usually spontaneous and complete and can be hastened by immunotherapy, especially intravenous immunoglobulin. 24 
Other causes of brainstem encephalitis
The differential diagnosis of a presentation of brainstem encephalitis includes:
• Infectious causes, the most common being Listeria species followed by enterovirus 71 and herpes simplex virus. 25 Tuberculosis, brucellosis, and Whipple disease should also be considered.
• Primary central nervous system inflammatory and demyelinating conditions, eg, multiple sclerosis and acute disseminated encephalomyelitis.
• Systemic inflammatory conditions, eg, Beh çet disease, systemic lupus erythematosus, and sarcoidosis.
• Direct brainstem neoplastic involvement, as might occur in primary central nervous system lymphoma or leptomeningeal carcinomatosis. Good (three cases reported, two improved) ANNA = antineuronal nuclear antibody; GAD = glutamic acid decarboxylase; GQ1b = ganglioside GQ1b; mGLuR1 = metabotropic glutamate receptor type 1; NMDA = N-methyl-d-aspartate; NMO = neuromyelitis optica; VGCC = voltage-gated calcium channel ■ CEREBELLAR SYNDROME
Patients with autoantibody-mediated encephalitis localized predominantly to the cerebellum typically present with dizziness, vertigo, and unsteady gait, progressing eventually to limb and gait ataxia. 4 Symptoms are often subacute, progressing over weeks.
Multiple neuronal autoantibodies have been found to occur with cerebellar encephalitis ( Table 2) . In most cases, they are paraneoplastic and considered not to be pathogenic, given the intracellular location of their target antigen. 4 In such cases, the syndrome is more accurately described as autoantibody-associated rather than autoantibody-mediated. Only in a minority of cases have neuronal autoantibodies been demonstrated to be directly pathogenic, ie, antimetabotropic glutamate receptor type 1 (anti-mGluR1) antibody-associated cerebellitis 26 and antiglutamic acid decarboxylase (anti-GAD)-associated cerebellar ataxia. 27 
Differential diagnosis of cerebellar syndromes
The differential diagnosis of autoantibodyassociated cerebellar syndromes is broad and includes:
• Alcohol-induced atrophy • Drug-induced cerebellar atrophy (eg, from lithium, phenytoin, gabapentin, metronidazole, amiodarone, carbamazepine) • Vitamin B 1 and E deficiency • Hypothyroidism, hypoparathyroidism • Neurodegenerative disease (eg, prion disease, multiple system atrophy) • Parainfectious causes (eg, after infection with Epstein-Barr virus) • Immune-mediated diseases (Miller-Fisher syndrome, associated with anti-GQ1b antibodies, and antigliadin-associated ataxia, which can occur in isolation or as part of celiac disease).
■ SYNDROMES ASSOCIATED WITH SPECIFIC ANTIBODIES
A few of the autoantibody-mediated encephalitic syndromes have specific antibody associations and characteristic clinical presentations. The most prominent of these syndromes are VGKC complex antibody encephalitis (as in the patient described at the beginning of this article) and anti-NMDA receptor encephalitis.
■ VGKC COMPLEX ANTIBODY-MEDIATED LIMBIC ENCEPHALITIS
VGKC complex antibodies, initially reported to be associated with the peripheral nerve hyperexcitability disorder neuromyotonia, were subsequently found in Morvan syndrome. 28, 29 Patients with this syndrome often present with autonomic dysfunction and peripheral nerve hyperexcitability but also develop insomnia, confusion, hallucinations, and memory loss. Drawing on the clinical overlap between Morvan syndrome and limbic encephalitis, Buckley et al 30 were the first to report VGKC complex antibodies in two cases of limbic encephalitis.
VGKC complex antibodies are now understood to be associated with a wide variety of neurologic conditions, including chronic idiopathic pain, epilepsy, 31 movement disorders, cranial nerve abnormalities, autonomic dysfunction, 32 and gut dysmotility. 33 In contrast, these antibodies are rare in healthy people. 34 Limbic encephalitis associated with VGKC complex antibody usually lacks cerebellar and brainstem dysfunction, which may help distinguish it from other types of autoantibodymediated limbic encephalitis. 12 VGKC complex antibody does not bind to the potassium channel itself. Instead it recognizes other constituents of the channel complex, most notably LGI1 and contactinassociated protein 2 (CASPR2).
LGI1 antibody is more commonly associated with limbic encephalitis-as illustrated in our case study-in addition to a distinctive type of seizure affecting the arm and face (faciobrachial dystonic seizure). 34 The CASPR2 antibody, on the other hand, more often correlates with peripheral nerve manifestations and Morvan syndrome. 29 Hyponatremia is commonly seen on serum chemical analysis and provides a clue that these syndromes are present.
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Good response to immunotherapy A critical change in therapy came as clinicians realized that seizures were often refractory to standard antiepileptic drugs but responded well to immunotherapies. On the basis Limbic encephalitis is now recognized to occur in the absence of malignancy of these observations, sera of patients with long-standing epilepsy have been reanalyzed to look for neuronal autoantibodies. 31 These antibodies should be checked in cases of newonset refractory status epilepticus of unknown origin that does not respond to antiepileptic medications.
About half of patients with VGKC complex antibody-mediated limbic encephalitis have normal findings on brain MRI. 5 Seven of 10 patients who were prospectively followed for VGKC complex antibody-mediated faciobrachial dystonic seizures had normal brain MRIs. 35 VGKC complex antibody-mediated limbic encephalitis does not usually recur. 36 Most cases are nonparaneoplastic, as evidenced by failure to detect a single active tumor in 64 patients after a median follow-up of 3 years. The prognosis is generally favorable except in cases with coexisting tumors.
■ ANTI-NMDA RECEPTOR ENCEPHALITIS
Often associated with ovarian teratoma Anti-NMDA receptor encephalitis typically affects women in their 20s and 30s, and about half of patients have an ovarian teratoma. It can also occur in younger patients and in men, in whom it is less likely to be associated with a neoplasm. 37 Typical initial symptoms include striking and often stereotyped neuropsychiatric disturbances manifesting as psychosis, confusion, seizures, and amnesia. After 1 to 2 weeks, new symptoms set in, including reduced consciousness, movement disorders (ranging from orolingualfacial dyskinesia to rigidity and choreoathetosis), autonomic dysfunction, and hypoventilation, often prompting admission to the intensive care unit. 38 Although the outcome is favorable in most cases, recovery, in contrast to VGKC complex antibody-mediated limbic encephalitis, is slow and may take longer than 1 year. Up to a quarter of patients have a relapse, underscoring the importance of maintenance immunotherapy.
It is important to undertake an intensive search for possible ovarian and extraovarian teratomas in young women with this syndrome-including CT of the pelvis, vaginal ultrasonography, and PET imaging-as removal of the teratoma may be curative. 37 
■ DIAGNOSIS OF AUTOANTIBODY-MEDIATED ENCEPHALITIS
Critical to diagnosing autoantibody-mediated encephalitis is awareness of these disorders. Antibody testing. None of these tests can be used in isolation, and the diagnosis of autoantibody-mediated encephalitis hinges on recognizing a clinical syndrome and ordering supportive testing. Specific antibodies are more likely in different clinical syndromes and should be sought ( Table 3) .
Patients who have autoantibody-mediated encephalitis may test negative for autoantibodies for many possible reasons:
• Blood testing for antibodies may be less sensitive than cerebrospinal fluid testing • Antibody titers may vary in the course of the disease
• The patient may be expressing an antibody that is less often tested for (eg, anti-AMPA receptor or antigamma-aminobutyric acid B) or one that has not yet been isolated. Evaluating for malignancy is recommended in all cases of autoantibody-mediated encephalitis. The initial workup may involve CT of the chest, abdomen, and pelvis, as well as mammography in women and serum prostate-specific antigen testing and testicular ultrasonography in men. Ordering FDG-PET in cases in which CT is negative or inconclusive increases cancer detection. 40 If no cancer is found, close tumor surveillance-every 3 to 6 months-is recommended for at least 2 years. Anti-glycine receptor Stiff person syndrome AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANNA = antineuronal nuclear antibody; CASPR2 = contactin-associated protein 2; CRMP = collapsin-responsive mediated protein; GABA B = gamma-aminobutyric acid B; LGI1 = leucine-rich glioma-inactivated protein 1; NMDA = N-methyl-d-aspartate
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■ TREATMENT
Owing in large part to the rarity of autoantibodymediated encephalitides, no randomized trials of therapy have been performed. Treatment at present is guided mostly by case series and expert consensus, which suggest first-line therapy with intravenous immunoglobulin, high-dose corticosteroids, plasmapheresis, or a combination. Different syndromes and antibody-related disorders respond differently to therapy. Syndromes associated with antibodies against intracellular antigens tend to be more resistant to immune therapy than cell surface antigenrelated syndromes. 4 
Tiered approach
Combined treatment with intravenous immunoglobulin and high-dose corticosteroids may be superior to treatment with steroids alone for LGI1-antibody mediated limbic encephalitis. 42 In cases refractory to first-line ("tier 1") therapy, second-line immunotherapy with drugs affecting B-cell populations (eg, rituximab, cyclophosphamide, and mycophenolate mofetil) has been used.
A tiered approach has been most extensively studied for anti-NMDA-receptor encephalitis, with better outcomes found using second-line therapy. 43 Treatment strategies for these disorders will likely evolve over time with additional experience.
Outpatient management
Once the patient is discharged from the hospital, a multidisciplinary approach to care is recommended, including physical rehabilitation, speech therapy, neuropsychiatric and neuroimmunologic follow-up, and annual surveillance for malignancies. 
